BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted ...

A person’s “bioenergetic age”, or how youthfully their cells generate energy, might be a key indicator of whether they’re at ...

Bioenergetic age, or how efficiently cells produce energy, could predict Alzheimer’s risk, with healthy lifestyle choices ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...

A person's 'bioenergetic age' -- or how youthfully their cells generate energy -- might be a key indicator of whether they're at risk of developing Alzheimer's disease, new research shows. The study ...

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi ...

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly ...

Its approval succeeds both the FDA’s accelerated and traditional approvals of Eisai and Biogen’s lecanemab (also known as Leqembi), a similar treatment, in early and mid-2023 respectively.

Chicago area scientists have identified the genes that drive the process of Alzheimer’s disease and are working to make the drug Lecanemab even better by identifying which genes are active ...